drugset
drugset / Trial / NCT05143905

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants

NCT05143905 ↗

Phase 1 Completed 56 enrolled AstraZeneca
RandomizedSequentialDouble-blindTreatment

Summary

This study will evaluate safety, tolerability and pharmacokinetics (PK) of AZD7503, following subcutaneous (SC) administration of single ascending doses of AZD7503 in healthy participants.

Timeline

Start
2021-12-06
Primary completion
2022-11-09
Completion
2022-11-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD7503 Unknown — Subcutaneous

Indications

No indication recorded.